Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Executive Summary
Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA
You may also be interested in...
Abbott GMP Investments “Pay Off” In Pharma, Despite Diagnostics Setback
Abbott's efforts to address quality control issues in the diagnostics division have had a beneficial effect on the company's GMP compliance status in pharmaceuticals, the company told a June 11 conference call
Abbott GMP Investments “Pay Off” In Pharma, Despite Diagnostics Setback
Abbott's efforts to address quality control issues in the diagnostics division have had a beneficial effect on the company's GMP compliance status in pharmaceuticals, the company told a June 11 conference call
Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients
Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic